Lv41
464 积分 2024-02-05 加入
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges
5天前
已完结
Influenza A(H3N2) Subclade K Virus
18天前
已完结
Process Development toward the Continuous Manufacturing of Baloxavir Marboxil
1个月前
已完结
First-Generation Process Development for the Synthesis of Baloxavir Marboxil: Early-Stage Development of Synthetic Methods to Prepare Baloxavir Marboxil Intermediates
1个月前
已完结
Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy Chinese participants: a first-in-human phase I clinical study
1个月前
已完结
Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial
2个月前
已完结
The Impact of Long COVID-19 on the Cardiovascular System
2个月前
已关闭
Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2/3 trial
2个月前
已完结
Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
2个月前
已完结
The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry
2个月前
已完结
皖公网安备34019202002308
